302 related articles for article (PubMed ID: 37507765)
21. Mechanisms of Drug Resistance in Melanoma.
Winder M; Virós A
Handb Exp Pharmacol; 2018; 249():91-108. PubMed ID: 28275910
[TBL] [Abstract][Full Text] [Related]
22. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
23. The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.
Ascierto PA; Warner AB; Blank C; Caracò C; Demaria S; Gershenwald JE; Khushalani NI; Long GV; Luke JJ; Mehnert JM; Robert C; Rutkowski P; Tawbi HA; Osman I; Puzanov I
J Transl Med; 2022 May; 20(1):200. PubMed ID: 35538491
[TBL] [Abstract][Full Text] [Related]
24. Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives.
Malissen N; Grob JJ
Drugs; 2018 Aug; 78(12):1197-1209. PubMed ID: 30097888
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
Loo K; Daud AI
Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
[TBL] [Abstract][Full Text] [Related]
26. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Luke JJ; Flaherty KT; Ribas A; Long GV
Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
[TBL] [Abstract][Full Text] [Related]
27. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
Devji T; Levine O; Neupane B; Beyene J; Xie F
JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
[TBL] [Abstract][Full Text] [Related]
28. The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020.
Ascierto PA; Atkins MB; Eggermont AM; Gershenwald JE; Grob JJ; Hamid O; Sondak VK; Sosman JA; Tawbi HA; Weber JS; Caracò C; Osman I; Puzanov I
J Transl Med; 2021 Apr; 19(1):142. PubMed ID: 33827575
[TBL] [Abstract][Full Text] [Related]
29. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.
Willsmore ZN; Coumbe BGT; Crescioli S; Reci S; Gupta A; Harris RJ; Chenoweth A; Chauhan J; Bax HJ; McCraw A; Cheung A; Osborn G; Hoffmann RM; Nakamura M; Laddach R; Geh JLC; MacKenzie-Ross A; Healy C; Tsoka S; Spicer JF; Josephs DH; Papa S; Lacy KE; Karagiannis SN
Eur J Immunol; 2021 Mar; 51(3):544-556. PubMed ID: 33450785
[TBL] [Abstract][Full Text] [Related]
30. [Combination strategies for checkpoint inhibition: Current practices and perspectives].
Dussart C; Decaux-Tramoni B; Quesada S; Thomas QD; Benzerouale O; Nicolas E; Fiteni F
Bull Cancer; 2023; 110(7-8):790-801. PubMed ID: 37055309
[TBL] [Abstract][Full Text] [Related]
31. Advances in immunotherapy for melanoma.
Redman JM; Gibney GT; Atkins MB
BMC Med; 2016 Feb; 14():20. PubMed ID: 26850630
[TBL] [Abstract][Full Text] [Related]
32. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis.
An Q; Liu Z
BMC Cancer; 2019 Jan; 19(1):43. PubMed ID: 30626368
[TBL] [Abstract][Full Text] [Related]
35. Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022).
Ascierto PA; Avallone A; Bifulco C; Bracarda S; Brody JD; Emens LA; Ferris RL; Formenti SC; Hamid O; Johnson DB; Kirchhoff T; Klebanoff CA; Lesinski GB; Monette A; Neyns B; Odunsi K; Paulos CM; Powell DJ; Rezvani K; Segal BH; Singh N; Sullivan RJ; Fox BA; Puzanov I
J Transl Med; 2023 Jul; 21(1):488. PubMed ID: 37475035
[TBL] [Abstract][Full Text] [Related]
36. TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.
Hodi FS; Wolchok JD; Schadendorf D; Larkin J; Long GV; Qian X; Saci A; Young TC; Srinivasan S; Chang H; Tang H; Wind-Rotolo M; Rizzo JI; Jackson DG; Ascierto PA
Cancer Immunol Res; 2021 Oct; 9(10):1202-1213. PubMed ID: 34389558
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
38. Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma.
Assi HI; Assi RE
Curr Cancer Drug Targets; 2017; 17(2):137-157. PubMed ID: 27628745
[TBL] [Abstract][Full Text] [Related]
39. [Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades].
Okuyama R
Gan To Kagaku Ryoho; 2016 Jun; 43(6):661-5. PubMed ID: 27306802
[TBL] [Abstract][Full Text] [Related]
40. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy).
Ascierto PA; Butterfield LH; Campbell K; Daniele B; Dougan M; Emens LA; Formenti S; Janku F; Khleif SN; Kirchhoff T; Morabito A; Najjar Y; Nathan P; Odunsi K; Patnaik A; Paulos CM; Reinfeld BI; Skinner HD; Timmerman J; Puzanov I
J Transl Med; 2021 Jan; 19(1):13. PubMed ID: 33407605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
